Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 The subsequent antitumor therapies prescribed to the enrolled hepatocellular carcinoma patients after diagnosis of tumor recurrence

From: Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety

Antitumor therapy Hepatectomy-TACE group (n = 56) Hepatectomy Alone group (n = 46) P-value
Locoregional ablation 27 8 < 0.001
Hepatectomya 2 2 1.000
Systemic chemotherapy 1 5 0.210
Sorafenib 14 5 0.029
TACE 12 26 0.016
  1. Hepatectomy-TACE: radical hepatectomy followed by adjuvant transcatheter arterial chemoembolization; Hepatectomy Alone: had undergone only radical hepatectomy
  2. a Resection of the recurrent lesion(s) in the liver